February 24, 2012
The Pharmaceutical and Food Safety Bureau’s Evaluation and Licensing Division issued a director notification dated February 15 to inform prefectures that Novartis Pharma’s pasireotide (expected indication: Cushing’s disease) has been designated as an orphan drug. Cushing’s disease is a rare...read more